Suchergebnisse

More than forty states worldwide currently pursue explicit political strategies to expand and promote their bioeconomies. This paper assesses these strategies in the context of the global Sustainable Development Goals (SDGs). Our theoretical framework differentiates between four pathways of bioeconomic developments. The extent to which bioeconomic developments along these pathways lead to increased sustainability depends on the creation of effective governance mechanisms. We distinguish between enabling governance and constraining governance as the two fundamental political challenges in setting up an effective governance framework for a sustainable bioeconomy. Further, we lay out a taxonomy of political support measures (enabling governance) and regulatory tools (constraining governance) that states can use to confront these two political challenges. Guided by this theoretical framework, we conduct a qualitative content analysis of 41 national bioeconomy strategies to provide systematic answers to the question of how well designed the individual national bioeconomy strategies are to ensure the rise of a sustainable bioeconomy.

"Monsanto Research Corporation a subsidiary of Monsanto Company"--Cover. ; "Mound Laboratory, Miamisburg, Ohio, operated for United States Atomic Energy Commission, U.S. Government Contract Number AT 33-1-GEN-53." ; "Date: June 1, 1964 ; Issued: November 27, 1964." ; "MLM-1202 ; TID-4500 (30th ed.) ; UC-34 Physics." ; U.S. Atomic Energy Commission Contract ; Mode of access: Internet.

Die Wissenschaftsplattform Nachhaltigkeit 2030 (wpn2030) begleitet u. a. den Staatssekretärsausschuss für nachhaltige Entwicklung mit wissenschaftlichen Impulsen. Für diesen Anlass wie auch für weitere wissensbasierte Politikprozesse wurde das DNS-Lab als Format entwickelt und nun erstmals umgesetzt. In kurzer Zeit, einem halben Tag, werden bestehendes Wissen und Perspektiven zu einem bestimmten Thema aus einem breiten transdisziplinären Spektrum integriert, verdichtet und daraus entsprechende Impulse entwickelt. Das DNS-Lab "Politiken für nachhaltigen Konsum stärken" fand am 4. März statt mit Vertreter*innen von sechs Bundesressorts, aus dem Parlamentarischen Beirat für nachhaltige Entwicklung (PBnE) und mit Expert*innen aus Wissenschaft, Wirtschaft und Gesellschaft. Den Teilnehmenden danken wir für ihre Beiträge. Der vorliegende Impuls speist sich aus den Lab-Ergebnissen sowie aus den Ergebnissen der wpn2030-Arbeitsgruppe "Nachhaltiger Konsum" von 2019 und knüpft an vorliegende Empfehlungen aus der Wissenschaft und an weitere Aktivitäten der jüngeren Vergangenheit an, wie beispielsweise an die 2020 vorlegte externe Evaluierung des Nationalen Programms für nachhaltigen Konsum (NPNK).

Introduction Surgical oncology is a defined specialty within the European Board of Surgery within the European Union of Medical Specialists (UEMS). Variation in training and specialization still occurs across Europe. There is a need to align the core knowledge needed to fulfil the criteria across subspecialities in surgical oncology. Material and methods The core curriculum, established in 2013, was developed with contributions from expert advisors from within the European Society of Surgical Oncology (ESSO), European Society for Radiotherapy and Oncology (ESTRO) and European Society of Medical Oncology (ESMO) and related subspeciality experts. Results The current version reiterates and updates the core curriculum structure needed for current and future candidates who plans to train for and eventually sit the European fellowship exam for the European Board of Surgery in Surgical Oncology. The content included is not intended to be exhaustive but, rather to give the candidate an idea of expectations and areas for in depth study, in addition to the practical requirements. The five elements included are: Basic principles of oncology; Disease site specific oncology; Generic clinical skills; Training recommendations, and, lastly; Eligibility for the EBSQ exam in Surgical Oncology. Conclusions As evidence-based care for cancer patients evolves through research into basic science, translational research and clinical trials, the core curriculum will evolve, mature and adapt to deliver continual improvements in cancer outcomes for patients.